Covered recipient · General Payments record
MARK D KAUFMANN
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$151,975.21
- Reported across 293 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $26,920.00 | 9 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,540.00 | 4 |
| Honoraria | $2,850.00 | 1 |
| Food and Beverage | $2,227.21 | 34 |
| Travel and Lodging | $304.50 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $14,435.75 | 12 |
| Incyte Corporation | $13,414.59 | 5 |
| Biofrontera Inc. | $7,445.57 | 5 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $3,472.19 | 2 |
| Almirall LLC | $2,888.66 | 2 |
| UCB SA | $710.00 | 1 |
| Amgen Inc. | $346.65 | 4 |
| E.R. Squibb & Sons, L.L.C. | $201.40 | 4 |
| Galderma Laboratories, L.P. | $158.92 | 3 |
| ABBVIE INC. | $150.00 | 1 |
| Arcutis Biotherapeutics, Inc. | $101.99 | 2 |
| Janssen Biotech, Inc. | $96.16 | 1 |
| Regeneron Pharmaceuticals, Inc. | $89.32 | 1 |
| Journey Medical Corporation | $57.96 | 1 |
| Verrica Pharmaceuticals Inc. | $54.75 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $48.46 | 1 |
| GENZYME CORPORATION | $46.83 | 1 |
| Eli Lilly and Company | $46.10 | 1 |
| LEO Pharma Inc. | $41.13 | 1 |
| UCB, Inc. | $35.28 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (50)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.